|
1) 小川 聡, 相澤義房, 是恒之宏, 他. 心房細動治療(薬物)ガイドライン(2008年改訂版). Circ J. 2008; 72 Suppl IV: 1640-58
|
|
|
|
|
2) Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-70
|
|
|
|
|
3) Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation. Japan Atrial Fibrillation Trial. Stroke. 2006; 37: 447-51
|
|
|
|
|
|
4) Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003; 362: 1691-8
|
|
|
|
|
|
5) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51
|
|
|
|
|
|
6) Turpie AG, Fisher WD, Bauer KA, et al. Odixa-Knee Study Group. BAY59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Heamost. 2005; 3: 2479-86
|
|
|
|
|
|
7) Furugohri T, Isobe K, Honda Y, et al. Pharmacological characterization, antithrombotic and bleeding effects of DU-176b, a novel, potent and orally active direct inhibitor of factor Xa: a wider safety margin of antithrombotic and bleeding effects compared to heparin, LMWH and warfarin. J Thromb Haemost. 2005; 3 Suppl 1: 1110
|
|
|
|
|
|
8) Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005; 3; 1843-53
|
|
|
|
|